1. < Prostate Cancer

Prostate cancer: Any further options?

Posted by bluffitis @bluffitis, Dec 8, 2020

Diagnosed 2.5 years ago with Gleason 9 all 12 cores and PSA of 76

Treated at Mayo Jax - 6 rounds of taxotere chemo, PSA down to 0.75.

On quarterly Lupron and Zometa

PSA started increasing about 6 months later

14 months on Zytiga before it became ineffective

Used Xtandi for 6 months and it’s become ineffective

Guardant 360 and Foundationone genomic tests results show no gene mutations to support immunotherapy

Also tested for eligibilibility for one clinical trial and was found to be ineligible

PSA back to 71 today

Started jevtana chemo today. Oncologist says based on current available treatment options and trials, we don’t have any other options

Are we missing any available options?

Interested in more discussions like this? Go to the Prostate Cancer Support Group.

itterac | @itterac | Oct 27, 2021
In reply to @norske46 "Watch for the release of 177Lu-PSMA-617 expected in first quarter 2022. It may provide an additional..." + (show)
@norske46

Watch for the release of 177Lu-PSMA-617 expected in first quarter 2022. It may provide an additional treatment. My oncologist is watching it closely. My PSA has gone ftom 541 down to as low as 5.5 now it is back to 264.2. I have used bicalutamide, lupron every six months, radiation (44 doses), zoledronic acid (every three months), and enzalutamide. I am about to start radium 223 treatment.. l have not t used docetaxel but may in the future. We are watching 177Lu-PSMA-617 as a possible treatment in the future. You may want to talk to your doctor about it.

Jump to this post

What is 177upsma617

REPLY
norske46 | @norske46 | Oct 27, 2021

I am not a doctor or a scientist, just a retired historian, but the way I understand it, 177Lu-PSMA-617 is a new isotope which has been in clinical trials and is expected to be approved by the FDA in the first quarter of 2022. I understand the drug works by identifying prostate cancer cells in the body, attaches itself to the cell and releases radiation into the cell to kill it. It all sounds very promising to me. My oncologist is watching it closely as a possible treatment option for me. Perhaps someone from Mayo can describe it better than I

REPLY
1 reply
itterac | @itterac | Oct 28, 2021

Thanks for response. I’ll follow too

REPLY
Moderator
Colleen Young, Connect Director | @colleenyoung | Oct 29, 2021
In reply to @norske46 "I am not a doctor or a scientist, just a retired historian, but the way I..." + (show)
@norske46

I am not a doctor or a scientist, just a retired historian, but the way I understand it, 177Lu-PSMA-617 is a new isotope which has been in clinical trials and is expected to be approved by the FDA in the first quarter of 2022. I understand the drug works by identifying prostate cancer cells in the body, attaches itself to the cell and releases radiation into the cell to kill it. It all sounds very promising to me. My oncologist is watching it closely as a possible treatment option for me. Perhaps someone from Mayo can describe it better than I

Jump to this post

I think you described it very well, Norske.

Here's how Novartis explains it in their press release: https://www.novartis.com/news/media-releases/novartis-announces-positive-result-phase-iii-study-radioligand-therapy-177lu-psma-617-patients-advanced-prostate-cancer

"Lu-PSMA-617 is an investigational PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer. It is a type of precision cancer treatment combining a targeting compound (ligand) with a therapeutic radioisotope (a radioactive particle). After administration into the bloodstream, 177Lu-PSMA-617 binds to prostate cancer cells that express PSMA13, a transmembrane protein, with high tumor-to-normal tissue uptake. Once bound, emissions from the radioisotope damage tumor cells, disrupting their ability to replicate and/or triggering cell death. The radiation from the radioisotope works over very short distances to limit damage to surrounding cells."

REPLY
norske46 | @norske46 | Oct 29, 2021

Thank you, Colleen , for your reference to the Novartis media notice. I had not seen it.

I begin my Radium223 treatment on November 3. We are praying for good outcomes.

REPLY
norske46 | @norske46 | Feb 15, 2022

Has anyone seen any updates on Lu177-PSMA-617--particularly: has it received FDA approval?

In the meantime, I continue with my Radium223 treatment and will receive my fourth dose next week. The main side effect has been weakness/tiredness.

REPLY
View MoreView Less
Please sign in or register to post a reply.